Mivebresib, Catalog: B1564

Alternate Names N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide;  ABBV-075

Appearance Crystalline solid

CAS # 1445993-26-9 

Molecular Formula C₂₂H₁₉F₂N₃O₄S 

Molecular Weight 459.47

Purity ≥ 98% by HPLC

Solubility DMSO

SMILES CCS(=O)(=O)NC1=CC(=C(C=C1)OC2=C(C=C(C=C2)F)F)C3=CN(C(=O)C4=C3C=CN4)C

InChi InChI=1S/C22H19F2N3O4S/c1-3-32(29,30)26-14-5-7-19(31-20-6

InChi Key RDONXGFGWSSFMY-UHFFFAOYSA-N

PubChem CID 71600087

Storage Conditions -20°C

Shipping Conditions Gel Pack

Usage For Research Use Only! Not For Use in Humans.

Handling Do not take it internally. Wear a glove and mask when handling the product. Protect from air and moisture.

Mivebresib is a potent bromodomain and extra-terminal domain (BET) inhibitor with potential antineoplastic activity. BET inhibitors target proteins called bromodomains, which play a role in gene regulation and chromatin remodeling.

It disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo.

Mivebresib inhibits BET proteins, which are involved in regulating gene expression by binding to acetylated histones. By blocking the BET proteins' activity, mivebresib can interfere with gene transcription, particularly of genes that promote cancer cell growth and survival.